Furthermore, our study provides a rational preclinical basis to test the combination therapy of anti-PD1 plus high-dose AA in lung cancer and paves the way for testing promising combinations of the two drugs in preclinical studies of other cancer types. Here, PDCD1 is linked to cancer.